NZYM B Novozymes A/S Class B

Interim report Q1 2025

Interim report Q1 2025

Strong start to the year and confirmed full-year outlook

Ester Baiget, President & CEO:  “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with agility in these dynamic times”.

  • Strong organic sales growth of 11% including ~1pp from price. All sales areas with double-digit organic sales growth. Emerging markets organic sales growth at 15% and developed markets at 9%.
  • Adjusted EBITDA margin at 38.3%, up by 310bps.
  • Adjusted net profit increased by 27%.
  • NIBD/EBITDA at 1.1x.
  • Announcement on February 11 to acquire dsm-firmenich’s part of the feed enzyme alliance at a EUR 1.5bn cash consideration, expected to close in the second quarter.
  • Andrew Taylor announced on April 22 as new EVP Food & Beverages, joining the company no later than September 1, 2025.
  • 2025 outlook maintained: 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.



Please read the full announcement in PDF

Attachment



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

 PRESS RELEASE

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF Attachments

 PRESS RELEASE

Novonesis delivered 8% organic sales growth in the first nine months o...

Novonesis delivered 8% organic sales growth in the first nine months of 2025 Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.  COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO:  "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and i...

 PRESS RELEASE

8% organic sales growth after first nine months. Full-year organic sal...

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards. Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch